Correction to Lancet Diabetes Endocrinol 2019; 7: 356-67

No authors listed

Published Erratum

No authors listed. Lancet Diabetes Endocrinol. 2019 Nov.

. 2019 Nov;7(11):e22.

doi: 10.1016/S2213-8587(19)30323-7.

No abstract available

Erratum for

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A. Zinman B, et al. Lancet Diabetes Endocrinol. 2019 May;7(5):356-367. doi: 10.1016/S2213-8587(19)30066-X. Epub 2019 Mar 1. Lancet Diabetes Endocrinol. 2019. PMID: 30833170 Clinical Trial.